Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Preventive Cardiology
For women with known autoimmune diseases, how do you approach ASCVD risk stratification when deciding to start a statin or aspirin for primary prevention?
Related Questions
How do you factor in a positive family history of premature CAD into ASCVD risk estimation?
What is a reasonable way to treat statin-induced myalgia and what statin substitute would you consider using in the event the myalgia is not resolved?
Should low-intensity statins be favored to minimize the risk of diabetes onset while still offering cardiovascular benefit for patients with prediabetes where a statin is indicated?
Is there a role for routine stress testing in intermediate-high risk CAD patients with a significantly elevated coronary calcium score who are otherwise asymptomatic?
Which classes of medications are reasonable to consider in cases of acute pericarditis in a patient with G6PD deficiency?
When would you consider adding an SGLT2 inhibitor, MRA, and/or ARNI (in lieu of ACE inhibitor or ARB) when discharging patients following revascularization for acute MI with newly reduced LV systolic function?
Is bupropion, for tobacco cessation, safe in patients with a history of childhood seizures (either isolated or childhood epilepsy)?
What is your preferred choice of anticoagulant (VKA vs. DOAC) in patients with an LV thrombus and apical infarct?
For patients with hypertension who have normal filling pressures following right cardiac catheterization, can hypertension still be attributed to volume overload?
What are your top takeaways from ACC 2024?
